Drug Profile
Research programme: SN 38 immunoconjugates - Immunomedics
Alternative Names: Antibody-SN-38 conjugates; CD74-targeted milatuzumab-SN 38 immunoconjugates; Epratuzumab-SN 38; hA20-SN 38; hL243-SN-38; hLL2-SN 38; hPAM4-SN 38; IMMU-114-SN-38; milatuzumab-CL2A-SN 38; milatuzumab-CL2E-SN 38; Milatuzumab-SN 38Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Immunomedics
- Class Camptothecins; Drug conjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Lung cancer; Lymphoma; Malignant melanoma; Pancreatic cancer; Solid tumours
- Discontinued Haematological malignancies
Most Recent Events
- 28 Dec 2022 Discontinued - Preclinical for Haematological malignancies in USA (Parenteral)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences